Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で17.23%の成長率を示しています。
黒字転換
同社は黒字転換を果たし、最新の年間純利益はUSD です。
割高
同社の最新のPEは-1.47で、過去3年間の水準と比較して高値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は173.34M株で、前四半期比で27.12%減少しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は0.34です。